Background Device-based innovation in metabolic bariatric surgery (MBS) has proliferated under evidentiary standards that differ substantially from those for pharmaceuticals. This review examines the lifecycle of MBS devices, from regulatory approval to long-term outcomes. Methods We conducted a structured literature search of PubMed/MEDLINE, Embase, and Scopus for English-language publications from January 1990 through May 2026, supplemented by regulatory database searches (FDA, EUDAMED) updated to manuscript submission. Five device categories representing distinct regulatory pathways were selected a priori: adjustable gastric bands (LAGB), implantable gastric stimulation (IGS) and vagal blockade (VBLOC), endoluminal liners (EndoBarrier), and gastric clips (BariClip). Intragastric balloons were excluded as temporary, non-implanted devices with different regulatory and safety profiles. This is a narrative review that used systematic search methods for transparency; it does not claim to be a systematic review or meta-analysis. Results The LAGB received FDA approval in 2001 based on 3-year data showing 36.2% excess weight loss (EWL), despite an advisory panel voting 6 − 4 that 2-year data were inadequate. Ten-year follow-up from the Teen-LABS study (2025) demonstrated that, among adolescents with retained bands, median BMI was 51.1, a 9.2% increase from baseline in this adolescent cohort. Implantable gastric stimulation failed to show benefit in the sham-controlled SHAPE trial (11.8% vs. 11.7% EWL, p = 0.717). Vagal blockade (VBLOC) showed equivocal results in the ReCharge trial (26.1% vs. 16.9% EWL, missing its prespecified margin) yet received FDA approval in 2015 via the Humanitarian Device Exemption (HDE #H150003). The EndoBarrier received CE marking in 2009 and was widely adopted before being withdrawn; a subsequent rigorous sham-controlled trial (ENDO, 2025) confirmed efficacy but revealed a 3.3% hepatic abscess rate. The BariClip, lacking FDA approval and an active MDR CE mark (EUDAMED search performed April 15, 2026, found no active certificate), has been studied only in small single-center series with short-term follow-up (6–24 months). Conclusions The history of device innovation in MBS reveals a recurring pattern: regulatory approval or market entry based on limited evidence, followed by gradual recognition of limited efficacy and device-specific complications. As noted in a companion systematic review, these failures are not limited to devices but reflect a broader systemic challenge. Structured oversight, including prospective registration, sham-controlled trials where feasible, post-market registries, and long-term follow-up requirements, is essential to protect patients and preserve the credibility of the field.
From Approval to Evidence: Device Regulation, Long-Term Outcomes, and Conflicts of Interest in Metabolic Bariatric Surgery
Papadia, Francesco Saverio
2026-01-01
Abstract
Background Device-based innovation in metabolic bariatric surgery (MBS) has proliferated under evidentiary standards that differ substantially from those for pharmaceuticals. This review examines the lifecycle of MBS devices, from regulatory approval to long-term outcomes. Methods We conducted a structured literature search of PubMed/MEDLINE, Embase, and Scopus for English-language publications from January 1990 through May 2026, supplemented by regulatory database searches (FDA, EUDAMED) updated to manuscript submission. Five device categories representing distinct regulatory pathways were selected a priori: adjustable gastric bands (LAGB), implantable gastric stimulation (IGS) and vagal blockade (VBLOC), endoluminal liners (EndoBarrier), and gastric clips (BariClip). Intragastric balloons were excluded as temporary, non-implanted devices with different regulatory and safety profiles. This is a narrative review that used systematic search methods for transparency; it does not claim to be a systematic review or meta-analysis. Results The LAGB received FDA approval in 2001 based on 3-year data showing 36.2% excess weight loss (EWL), despite an advisory panel voting 6 − 4 that 2-year data were inadequate. Ten-year follow-up from the Teen-LABS study (2025) demonstrated that, among adolescents with retained bands, median BMI was 51.1, a 9.2% increase from baseline in this adolescent cohort. Implantable gastric stimulation failed to show benefit in the sham-controlled SHAPE trial (11.8% vs. 11.7% EWL, p = 0.717). Vagal blockade (VBLOC) showed equivocal results in the ReCharge trial (26.1% vs. 16.9% EWL, missing its prespecified margin) yet received FDA approval in 2015 via the Humanitarian Device Exemption (HDE #H150003). The EndoBarrier received CE marking in 2009 and was widely adopted before being withdrawn; a subsequent rigorous sham-controlled trial (ENDO, 2025) confirmed efficacy but revealed a 3.3% hepatic abscess rate. The BariClip, lacking FDA approval and an active MDR CE mark (EUDAMED search performed April 15, 2026, found no active certificate), has been studied only in small single-center series with short-term follow-up (6–24 months). Conclusions The history of device innovation in MBS reveals a recurring pattern: regulatory approval or market entry based on limited evidence, followed by gradual recognition of limited efficacy and device-specific complications. As noted in a companion systematic review, these failures are not limited to devices but reflect a broader systemic challenge. Structured oversight, including prospective registration, sham-controlled trials where feasible, post-market registries, and long-term follow-up requirements, is essential to protect patients and preserve the credibility of the field.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
